Data Insights

AUTO-1/22 by Autolus Therapeutics for Hairy Cell Leukemia: Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Hairy Cell Leukemia. According to GlobalData,...

Data Insights

AUTO-1/22 by Autolus Therapeutics for Burkitt Lymphoma: Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Burkitt Lymphoma

Data Insights

AUTO-1/22 by Autolus Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

AUTO-1/22 by Autolus Therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Data Insights

AUTO-1/22 by Autolus Therapeutics for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Chronic Lymphocytic Leukemia (CLL)

Data Insights

AUTO-1/22 by Autolus Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

AUTO-1/22 by Autolus Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - AUTO-1/22 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)